Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy

February 26, 2024

KEYTRUDA Significantly Improved DFS as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized MIBC After Surgery

February 26, 2024

DREAMM-7 Ph 3 trial shows Blenrep combination nearly tripled mPFS vs SOC combination in patients with R/R multiple myeloma

February 26, 2024

SC Nivolumab Shows Noninferiority Compared to IV Opdivo (nivolumab) in Advanced or Metastatic ccRCC in CheckMate -67T Trial

February 26, 2024

Preliminary DCR of 61% reported in evaluable Ph 2 advanced breast cancer patients treated with Bria-IMT

February 26, 2024

Final Results of Ph 3 ASCERTAIN Trial of Oral Decitabine and Cedazuridine Fixed Dose Combination (INQOVI®) in Patients With MDS and CMML published

February 16, 2024

FAILED TRIAL: Ph 3 EVOKE-01 study did not meet primary endpoint of OS in previously treated metastatic NSCLC

January 31, 2024

Complete Remission Of The Cohort 1 First Patient Treated For R/R B-ALL In Ph 1 Trial Of PMB-CT01 (BAFFR-CAR T Cells) announced

January 31, 2024

Opdivo + CABOMETYX Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC

January 31, 2024

KEYTRUDA Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery

January 31, 2024

KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy

January 31, 2024

Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolisation

January 23, 2024

Data from Ph 1b Study of Quemliclustat-Based Regimens Showed Promising OS in Treatment-Naïve Metastatic Pancreatic Cancer

January 23, 2024

Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer Provided

January 17, 2024

Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia Announced

January 10, 2024

Scemblix Shows Superior MMR Rates Vs. SoC TKIs In Ph 3 Trial For Newly Diagnosed Patients With CML

January 10, 2024

Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma announced

January 10, 2024

Jemperli + Zejula combination significantly improved PFS in primary advanced or recurrent endometrial cancer in RUBY Part 2 Ph 3 trial

January 4, 2024

FAILED TRIAL: CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued

January 4, 2024

Positive Immune Response and Survival Data reported in Completed Ph 1 Study of Galinpepimut-S + Opdivo in Advanced Malignant Pleural Mesothelioma

January 4, 2024

Unprecedented Preliminary Survival and Clinical Benefit reported in Antibody-Drug Conjugate (ADC) Refractory Patient Subset treated with Bria-IMT™ regimen

January 4, 2024

71% Central Nervous System Response Rate in Advanced Breast Cancer Patients reported

January 4, 2024

Fostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development plan

January 4, 2024

Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin announced

January 4, 2024

FAILED TRIAL: RELATIVITY-123 Trial Evaluating the Fixed-Dose Combo of Opdivo + Relatlimab in Previously Treated MSS CRC Patients unlikely to meet primary endpoint, to be discontinued

December 19, 2023
Page1 … Page13 Page14 Page15 Page16 Page17 … Page29

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.